150 related articles for article (PubMed ID: 10980634)
1. Unmanipulated peripheral blood stem cell autograft in chronic lymphocytic leukemia: clinical findings and biological monitoring.
Meloni G; Proia A; Mauro F; Amaranto P; Capria S; Cimino G; Cordone I; de Fabritiis P; Rapanotti C; Reato G; Vignetti M; Foa R; Mandelli F
Haematologica; 2000 Sep; 85(9):952-60. PubMed ID: 10980634
[TBL] [Abstract][Full Text] [Related]
2. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.
Montillo M; Cafro AM; Tedeschi A; Brando B; Oreste P; Veronese S; Rossi V; Cairoli R; Pungolino E; Morra E
Haematologica; 2002 Jul; 87(7):695-700; discussion 700. PubMed ID: 12091119
[TBL] [Abstract][Full Text] [Related]
4. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
[TBL] [Abstract][Full Text] [Related]
5. Conventional hematopoietic stem cell transplants from identical or alternative donors are feasible in recipients relapsing after an autograft.
di Grazia C; Raiola AM; Van Lint MT; Lamparelli T; Gualandi F; Berisso G; Bregante S; Dominietto A; Mordini N; Bruno B; Frassoni F; Bacigalupo A
Haematologica; 2001 Jun; 86(6):646-51. PubMed ID: 11418375
[TBL] [Abstract][Full Text] [Related]
6. Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia.
Pfitzner T; Reiser M; Barth S; Borchmann P; Schulz H; Schinköthe T; Oberhäuser F; Wessels J; Tur M; Diehl V; Engert A
Ann Hematol; 2002 May; 81(5):258-66. PubMed ID: 12029535
[TBL] [Abstract][Full Text] [Related]
7. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation.
Martinelli G; Terragna C; Zamagni E; Ronconi S; Tosi P; Lemoli R; Bandini G; Testoni N; Amabile M; Ottaviani E; Buonamici S; Soverini S; Montefusco V; de Vivo A; Bonifazi F; Tura S; Cavo M
Haematologica; 2000 Sep; 85(9):930-4. PubMed ID: 10980631
[TBL] [Abstract][Full Text] [Related]
8. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.
Aversa F; Terenzi A; Tabilio A; Falzetti F; Carotti A; Ballanti S; Felicini R; Falcinelli F; Velardi A; Ruggeri L; Aloisi T; Saab JP; Santucci A; Perruccio K; Martelli MP; Mecucci C; Reisner Y; Martelli MF
J Clin Oncol; 2005 May; 23(15):3447-54. PubMed ID: 15753458
[TBL] [Abstract][Full Text] [Related]
9. Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study.
Schey S; Ahsan G; Jones R
Bone Marrow Transplant; 1999 Nov; 24(9):989-93. PubMed ID: 10556958
[TBL] [Abstract][Full Text] [Related]
10. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
[TBL] [Abstract][Full Text] [Related]
11. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
13. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy.
O'Brien S; Kantarjian H; Beran M; Robertson LE; Koller C; Lerner S; Keating MJ
Blood; 1995 Aug; 86(4):1298-300. PubMed ID: 7632936
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
[TBL] [Abstract][Full Text] [Related]
16. Ten-year follow-up of a single center prospective trial of unmanipulated peripheral blood stem cell autograft and interferon-alpha in early phase chronic myeloyd leukemia.
Meloni G; Capria S; Vignetti M; Alimena G; de Fabritiis P; Montefusco E; Mandelli F
Haematologica; 2001 Jun; 86(6):596-601. PubMed ID: 11418368
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia.
Tóthová E; Kafková A; Fricová M; Guman T; Stecová N
Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065
[TBL] [Abstract][Full Text] [Related]
18. Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous stem cell transplantation.
Patriarca F; Gaidano G; Capello D; Zaja F; Fanin R; Baccarani M
Haematologica; 2000 Sep; 85(9):982-5. PubMed ID: 10980639
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
20. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
